Enumeral To Present At The Emerging Concepts In Host Response To Cancer Symposium At The University of Texas MD Anderson Cancer Center

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that the company will present a poster titled “Human Tumor-Based Identification of Immune Checkpoint Targets” at The University of Texas MD Anderson Cancer Center’s Emerging Concepts in Host Response to Cancer Symposium Symposia. Enumeral’s poster will highlight recent developments in the company’s PD-1 and TIM-3 antibody programs.

Help employers find you! Check out all the jobs and post your resume.